Exploring Therapeutic Decisions in Elderly Patients with Non-Small Cell Lung Cancer: Results and Conclusions from North Central Cancer Treatment Group Study N0222.

Autor:	Kean, Heidi Mc, Stella, Philip J., Hillman, Shauna L., Rowland, Kendrith M., Cannon, Michael W., Behrens, Robert J., Gross, Gerald G., Sborov, Mark D., Friedman, Eliot L., Jatoi, Aminah
Předmět:	SMALL cell lung cancer DISEASE progression ANTINEOPLASTIC agents CANCER treatment CANCER chemotherapy ONCOLOGISTS DRUG dosage PATIENTS
Zdroj:	Cancer Investigation; May2011, Vol. 29 Issue 4, p266-271, 6p, 3 Charts, 1 Graph
Abstrakt:	How do oncologists choose therapy for the elderly?? Oncologists assigned patients aged 65 years or older with incurable non-small cell lung cancer to: (a) carboplatin (AUC == 2) ++ paclitaxel 50 mg/m2 days 1, 8, 15 (28-day cycle ×× 4) followed by gefitinib; or (b) gefitinib 250  mg/day. With (a), 12 of 34 were progression-free at 6 months; median time to cancer progression was 3.9 months. With (b), the same occurred in 11 of 28 patients with the latter being 4.9 months. The most common reason for conventional chemotherapy was oncologists'' opinion that the cancer was aggressive, and for gefitinib alone, patients'' reluctance to receive chemotherapy. Interestingly, age had no influence. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.